AstraZeneca India announced its entry into rare disease therapy in India. The company received regulatory approval for its ‘Selumetinib’ for patients in India. Globally, more than 400 million people are affected by rare diseases, and currently, there are 7,000 identified and recorded rare diseases. AstraZeneca has partnered the Organization of...
AstraZeneca’s Biliary Tract Cancer Drug Receives Regulatory Approval in India
British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca PLC's India arm announced that it received additional indication approval from the Central Drugs Standard Control Organization (CDSCO) for the drug Durvalumab to treat biliary tract cancer (BTC) in India. BTC is a group of rare and aggressive gastrointestinal cancers that form in the...